HRP20251484T1 - Pojačano doziranje tableta rukapariba - Google Patents

Pojačano doziranje tableta rukapariba

Info

Publication number
HRP20251484T1
HRP20251484T1 HRP20251484TT HRP20251484T HRP20251484T1 HR P20251484 T1 HRP20251484 T1 HR P20251484T1 HR P20251484T T HRP20251484T T HR P20251484TT HR P20251484 T HRP20251484 T HR P20251484T HR P20251484 T1 HRP20251484 T1 HR P20251484T1
Authority
HR
Croatia
Prior art keywords
tablet according
tablet
active pharmaceutical
pharmaceutical ingredient
range
Prior art date
Application number
HRP20251484TT
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey Etter
Original Assignee
Pharma& Schweiz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma& Schweiz Gmbh filed Critical Pharma& Schweiz Gmbh
Publication of HRP20251484T1 publication Critical patent/HRP20251484T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20251484TT 2014-08-22 2015-08-17 Pojačano doziranje tableta rukapariba HRP20251484T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
EP15833096.9A EP3182975B1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (1)

Publication Number Publication Date
HRP20251484T1 true HRP20251484T1 (hr) 2026-01-02

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251484TT HRP20251484T1 (hr) 2014-08-22 2015-08-17 Pojačano doziranje tableta rukapariba

Country Status (23)

Country Link
US (3) US9987285B2 (https=)
EP (1) EP3182975B1 (https=)
JP (3) JP6574477B2 (https=)
KR (2) KR102803917B1 (https=)
CN (2) CN106794185A (https=)
AU (2) AU2015305696B2 (https=)
BR (1) BR112017000865A2 (https=)
CA (1) CA2955495C (https=)
DK (1) DK3182975T3 (https=)
ES (1) ES3048688T3 (https=)
FI (1) FI3182975T3 (https=)
HR (1) HRP20251484T1 (https=)
IL (1) IL249946B (https=)
LT (1) LT3182975T (https=)
MX (1) MX367260B (https=)
NZ (1) NZ728392A (https=)
PL (1) PL3182975T3 (https=)
PT (1) PT3182975T (https=)
RS (1) RS67356B1 (https=)
RU (1) RU2705156C2 (https=)
SG (1) SG11201700265VA (https=)
SI (1) SI3182975T1 (https=)
WO (1) WO2016028689A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Cgrp活性化合物の錠剤製剤
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마& 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
BR112019020211A2 (pt) 2017-03-27 2020-04-22 Tesaro, Inc. composições de niraparib
KR20250016494A (ko) * 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
EP4143182B1 (en) 2020-04-28 2024-12-11 Rhizen Pharmaceuticals AG Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023086784A1 (en) * 2021-11-10 2023-05-19 Crititech, Inc. Rucaparib particles and uses thereof
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
MXPA05010563A (es) 2003-03-31 2005-11-23 Pfizer Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
SI1660095T1 (sl) 2003-07-25 2010-05-31 Cancer Rec Tech Ltd Triciklični parp inhibitorji
EP1793830A2 (en) 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
EP1799685B1 (en) 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
DK1794163T3 (da) 2004-09-22 2010-04-12 Pfizer Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer
JP2011516527A (ja) 2008-04-09 2011-05-26 レツク・フアーマシユーテイカルズ・デー・デー 医薬品有効成分の造粒
EP2534153B2 (en) * 2010-02-12 2024-05-22 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
KR102803917B1 (ko) 2014-08-22 2025-05-07 파르마& 슈바이츠 게엠베하 루카파립의 고 용량 강도 정제

Also Published As

Publication number Publication date
RU2705156C2 (ru) 2019-11-05
US10130636B2 (en) 2018-11-20
RU2017109139A (ru) 2018-09-24
US20190099430A1 (en) 2019-04-04
JP6797980B2 (ja) 2020-12-09
ES3048688T3 (en) 2025-12-11
CA2955495C (en) 2023-09-19
CN106794185A (zh) 2017-05-31
JP7127101B2 (ja) 2022-08-29
SG11201700265VA (en) 2017-02-27
MX367260B (es) 2019-08-12
NZ728392A (en) 2023-06-30
PT3182975T (pt) 2025-10-28
KR20230097211A (ko) 2023-06-30
AU2015305696A1 (en) 2017-02-02
RS67356B1 (sr) 2025-11-28
EP3182975A1 (en) 2017-06-28
JP2017525712A (ja) 2017-09-07
AU2019272064A1 (en) 2019-12-19
RU2017109139A3 (https=) 2019-03-06
IL249946A0 (en) 2017-03-30
JP2020002149A (ja) 2020-01-09
LT3182975T (lt) 2025-11-25
PL3182975T3 (pl) 2026-02-23
MX2017001540A (es) 2017-05-11
EP3182975A4 (en) 2018-04-18
US20160051561A1 (en) 2016-02-25
KR102803917B1 (ko) 2025-05-07
CA2955495A1 (en) 2016-02-25
AU2015305696B2 (en) 2019-08-29
JP6574477B2 (ja) 2019-09-11
US9987285B2 (en) 2018-06-05
SI3182975T1 (sl) 2025-12-31
US20180200260A1 (en) 2018-07-19
EP3182975B1 (en) 2025-10-01
AU2019272064B2 (en) 2021-11-18
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
FI3182975T3 (fi) 2025-11-13
KR20170043597A (ko) 2017-04-21
JP2021038242A (ja) 2021-03-11
CN113209033A (zh) 2021-08-06
WO2016028689A1 (en) 2016-02-25
BR112017000865A2 (pt) 2017-12-05

Similar Documents

Publication Publication Date Title
HRP20251484T1 (hr) Pojačano doziranje tableta rukapariba
JP2017525712A5 (https=)
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
UA116334C2 (uk) Тверді форми дозування бендамустину
HRP20250604T1 (hr) Formulacije tableta neratinib maleata
SG190448A1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
IL273300B2 (en) High dose valbenazine formulation and related preparations, methods and kits
HRP20230616T1 (hr) Disperzivni pripravci
HRP20240564T1 (hr) Novi farmaceutski sastav
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
JP2018527305A5 (https=)
AR074739A1 (es) Comprimidos de capecitabina de disgregacion rapida
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
RU2016150178A (ru) Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция
HRP20161340T1 (hr) Formulacije darunavira
IL273754B1 (en) Fortified oral taxane preparations and methods
HRP20192184T1 (hr) Optimizirana visokodozna tableta mesalazina
FI3509595T3 (fi) Hydroksipyridonaattiaktinidi-/lantanididekorporaatioaineiden formulaatioita
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
RU2019105711A (ru) Фармацевтическая композиция, содержащая помалидомид
RU2017111887A (ru) Фармацевтические композиции
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture